Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Docetaxel, Liposomal doxorubicine and Cyclophosphamide
Sponsor: Grupo Oncológico Gallego
Collaborators: Pivotal S.L.